Lantheus Holdings, Inc.
NASDAQ:LNTH · NASDAQ Global Market
+$1.01 today
Vol 0.99M · Avg 0.94M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
21.4%
avg 61.4%
ROIC
12.2%
avg 12.3%
ROA
10.5%
avg 8.4%
Analysis
ROE is currently the strongest return metric at 21.4% versus its period average of 61.4%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Ludger Dinkelborg | Head of Research & Development | $13.66M | — | 63 | $35,731.00 | 0.05% |
Robert J. Marshall Jr. | Chief Financial Officer & Treasurer | $991,665.00 | — | 59 | $123,974.00 | 0.19% |
Jean-Claude Provost | Chief Science Officer | $894,790.00 | — | 63 | $38,841.00 | 0.06% |
Thomas Reiner | Chief Science Officer | $894,790.00 | — | — | — | — |
Daniel Niedzwiecki | Chief Administrative Officer, General Counsel & Corporate Secretary | $763,085.00 | — | 49 | $117,465.00 | 0.18% |
Amanda Morgan | Chief Commercial Officer | $677,449.00 | — | 47 | $64,748.00 | 0.10% |
Mary Anne Heino | Interim CEO & Executive Chairperson | $673,968.00 | — | 66 | $365,040.00 | 0.56% |
Dorothy Barr | Senior Vice President of Manufacturing & Technical Operations | — | — | — | — | — |
Mark Richard Kinarney | Vice President of Investor Relations | — | — | — | — | — |
Neil Holland | Vice President of Business Insights & Operations | — | — | — | — | — |
Kimberly Brown | Chief Accounting Officer | — | — | 35 | $13,859.00 | 0.02% |
Lee Anne Howe | Chief Information Officer | — | — | — | $365,040.00 | 0.56% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
5
$382.59M
Net Sentiment
$382.59M
Net selling
Most Active
FARALLON PARTNERS L L C/CA
2 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 5 sells worth $382.59M over the last 12 months. That adds up to net selling of $382.59M. FARALLON PARTNERS L L C/CA was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +0.6% | +14.3% (15yr)7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | +24.9% (15yr)7 analysts |
Analysis
Recent growth has been strongest in Revenue at +0.6% over three years. Forward estimates point to EBIT at +24.9% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
$6.03B
Amneal Pharmaceuticals, Inc.
NASDAQ:AMRX
$5.25B
Hinge Health, Inc.
NYSE:HNGE
$5.20B
Indivior Pharmaceuticals Inc
NASDAQ:INDV
$4.83B
Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
$3.81B
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
$3.71B
Supernus Pharmaceuticals, Inc.
NASDAQ:SUPN
$2.55B
ADMA Biologics, Inc.
NASDAQ:ADMA
$1.97B
HUTCHMED (China) Limited
NASDAQ:HCM
$1.82B
Bausch Health Companies Inc.
NYSE:BHC
$1.75B
Who manages LNTH?
Lantheus Holdings, Inc. (LNTH) lists 12 active executives. The top listed executive is Dorothy Barr, Senior Vice President of Manufacturing & Technical Operations.
Are LNTH insiders buying or selling?
Recent insider activity shows net selling of $399.66M.
Explore More
Continue the stock analysis
Jump to another research area for this company.